Opsona Therapeutics Limited

Spero Trinem, Inc.

Christopher Phillip Locher

Luke O'Neill

Brian Keogh

Mark Heffernan

Peter McGuirk

Paul S Charifson

Emanuele Perola

Anne-Laure Grillot

Arnaud Le Tiran

Hardwin O'Dowd

Youssef Laafiret Bennani

Peter Mcguirk

Fatih Arslan

Dominique De Kleijn

Gerard Pasterkamp

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

Combination therapy to treat mycobacterium diseases

[object Object]

The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.

Treatment of renal disease

The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.

Composition and method for treatment of reperfusion injury and tissue damage

The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.

Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody

Growing community of inventors

Lexington, MA, United States of America

Christopher Phillip Locher